Related Experiment Videos
Long-term prognosis of diffuse lupus nephritis
C Ponticelli1, P Zucchelli, G Moroni
1Division of Nephrology and Dialysis, Hospital Maggiore Policlinico, Milano, Italy.
Clinical Nephrology
|December 1, 1987
Summary
Long-term outcomes for diffuse proliferative lupus nephritis have improved significantly. Treatment with high-dose methylprednisolone pulses followed by steroids and cytotoxic drugs enhances kidney survival and reduces flare-ups.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Diffuse proliferative lupus nephritis (DPLN) is a severe manifestation of systemic lupus erythematosus.
- Long-term prognosis and optimal treatment strategies for DPLN remain critical areas of research.
Purpose of the Study:
- To evaluate the long-term outcomes of patients with DPLN treated with a specific regimen.
- To assess patient and kidney survival rates, renal function, and treatment-related side effects.
Main Methods:
- Follow-up of 43 patients diagnosed with DPLN.
- Treatment protocol included high-dose intravenous methylprednisolone pulses, followed by low-dose oral steroids.
- 31 patients also received cytotoxic drugs; exacerbations were treated with high-dose steroids.
Main Results:
- At 10 years, patient survival was 87% and kidney survival was 79% (91% excluding extra-renal deaths).
- Most patients maintained or recovered renal function; only 1 required regular dialysis.
- Low incidence of flare-ups (0.1 episodes/year) and rare severe side effects were observed.
Conclusions:
- The long-term prognosis for DPLN is improving considerably.
- A treatment approach using pulsed high-dose methylprednisolone and maintenance therapy with steroids and cytotoxic agents preserves renal function effectively.
- This regimen helps avoid severe side effects, contributing to better patient outcomes.